The company has secured 506 marketing approvals for its oncology products across 76 countries.
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Subscribe To Our Newsletter & Stay Updated
